CD52 and myeloid sarcoma: The efficacy of anti-CD52 therapy was also assessed in the EAE models, which allow to demonstrate both the immunosuppressive action of anti-CD52 antibody and parallel the long term ability of alemtuzumab to control disease in Relapsing Remitting MS (RRMS) patients [23]: Anti-murine CD52 antibody was able to reduce the number of circulating and CNS infiltrating antigen-specific T cells; EAE mice treated at early stages of the disease maintained stable disease up to 90 days without retreatment despite complete lymphocyte repopulation in the blood and lymphoid organs.